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Background: Rhodiola rosea L. root (Golden Root, Arctic Root) is a high-value herbal medicinal product, 10 
registered in the UK for the treatment of stress-induced fatigue, exhaustion and anxiety and used throughout 11 
Europe as a herbal medicinal product for similar indications. There are several Chinese species used in 12 
traditional Chinese medicine (TCM), including Rhodiola crenulata (Hook.f. & Thomoson) that is believed to be a 13 
common adulterant in the R. rosea value chain.  We investigate the phytochemistry of the different species 14 
and assess the potential of R. crenulata as an adulterant in the Rhodiola rosea value chain. 15 
Aims: The project is embedded in a larger study aiming to investigate the diverse value chains that lead to the 16 
production of Rhodiola rosea as a herbal medicinal product. Here we focus on a comparison of the quality of 17 
the finished products and assess any phytochemical variation between products registered under the 18 
Traditional Herbal Medicine Products Directive (THMPD) and products obtained from the market without any 19 
registration (i.e. generally unlicensed supplements).  20 
There are different species of Rhodiola on the market and the principal aim is to establish how these different 21 
species vary in their metabolite profile, how products are commercialised and whether there is potential for 22 
adulteration at the product manufacture stage.   23 
Methods: Approximately 40 commercial products have been sourced from different suppliers. We analysed 24 
these samples using high performance thin layer chromatography (HPTLC), mass spectrometry (MS) and  
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H-25 
NMR spectroscopy coupled with multi-variate analysis software following a method previously developed by 26 
our group for the analysis of turmeric products.  27 
Results: The consistency of the products varies significantly.  Approximately one fifth of commercial products 28 
that claimed to be Rhodiola rosea did not contain rosavin (one of the reference markers used to distinguish R. 29 
rosea from related species). Moreover some products appeared not to contain salidroside, another marker 30 
compound found in medicinal Rhodiola species. Approximately 80 % of the remaining commercial products 31 
were lower in rosavin content than the registered products and appeared to be adulterated with other 32 
Rhodiola species. 33 
Conclusions: The variation in phytochemical constituents present in Rhodiola products available to European 34 
buyers via the internet and other sources is a major cause for concern. Adulteration with different species, and 35 
other unknown adulterants, appears to be commonplace. Good quality systems and manufacturing practices, 36 
including those required under the THMPD, enable consumers to have confidence that products are authentic 37 
and meet a high specification for quality and safety.   38 
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 40 
 41 
2 
 
Abbreviations 42 
AMIX  Analysis of mixtures 43 
DMSO  Dimethylsulphoxide 44 
GACP  Good agricultural and collection practice 45 
GMP  Good manufacturing practice 46 
HMP  Herbal medicinal product 47 
HPTLC  High performance thin layer chromatography 48 
HTP  Hydroxytryptophan 49 
LC  Liquid chromatography 50 
MS  Mass spectrometry 51 
NMR   Nuclear magnetic resonance 52 
PCA  Principal component analysis 53 
PL  Product licence 54 
TCM  Traditional Chinese medicine 55 
THR  Traditional herbal registration 56 
THMPD  Traditional Herbal Medicinal Products Directive 57 
TMS  Tetramethylsilane 58 
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Introduction 70 
Sedum roseum (L.) Scop., Crassulaceae , mainly known within the medicinal plant industry under its synonym 71 
Rhodiola rosea L., is a perennial flowering plant distributed throughout the northern hemisphere, particularly 72 
in circumpolar and high altitude regions of Europe and Asia, and to a lesser extent in North America (Brown, 73 
2002).  74 
Over 200 Rhodiola species have been documented, and many of these are used as medicine in Asia, including 75 
Rhodiola heterodonta (Hook.f. & Thomson) Boriss, Rhodiola quadrifida (Pall.) Fisch & Mey, Rhodiola semenovii 76 
(Regel & Herder) Boriss, Rhodiola kirilowii (Regel) Maxim. and Rhodiola crenulata (Hook.f. & Thomson) 77 
H.Ohba. Among, all of these species, R. rosea has been the predominant subject of phytochemical, animal and 78 
human studies (Shikov, 2014). 79 
The root of Rhodiola rosea is mentioned in Carl Linne’s Materia Medica, which recommends it as a treatment 80 
for headaches, hysteria, and as an astringent. The traditional medicinal uses of R. rosea have been well 81 
established, and numerous studies have been carried out in-vitro and in-vivo concerning cardio-, neuro- and 82 
hepatoprotective effects, antiviral, anti-inflammatory and antibacterial activities of R. rosea extracts 83 
(Panossian et al., 2010). 84 
 R. rosea has a long history of use as a medicinal plant in several traditional systems. Between 1748 and 1961 a 85 
catalogue of medicinal applications of R. rosea appeared in the scientific literature of Sweden, Norway, France, 86 
Germany, Iceland, and the Soviet Union, principally as an adaptogen with various health-promoting effects 87 
(Panossian et al., 2010). 88 
The root of R. rosea is mainly wild-harvested, the main region being the Altai Mountains in southern Siberia 89 
(Galambosi, 2005). Although some attempts have been made to cultivate (e.g. Canada, Sweden, Bulgaria), 90 
there appears to be little interest for investment in large-scale cultivation. This may be due to the long-term 91 
nature of any investment (the root needs five years of growth before it can be harvested) or it may be that the 92 
costs involved make it difficult for farmers to compete on price with the wild-collected material. 93 
However, our initial investigations suggest that due to its popularity, there is a scarcity of authentic raw 94 
material available and not enough to satisfy demand. Because of this disparity between supply (at an 95 
acceptable price) and demand, there is potential for adulteration with different species, especially Rhodiola 96 
crenulata (Hook.f. & Thomson) H.Ohba and other Chinese species. 97 
With a traditional history of medicinal use within Eastern Europe, Scandinavia, arctic countries, Asia and North 98 
America – Rhodiola products have become high value commodities, traded internationally. One factor 99 
contributing towards this economic growth is its use by sports men and women to help prevent fatigue and 100 
improve performance (Parisi et al., 2010).  101 
Use of R. rosea and other Rhodiola species is allowed by sports regulators but this use highlights a potential 102 
danger that if adulterated products are unknowingly used, the reputation of sports competitors could be 103 
adversely affected. 104 
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Herbal products, advertised as containing the root of R. rosea, are widely available from retails outlets and the 105 
internet. They are generally sold as ‘food supplements’ and so providing they do not make any medicinal claim 106 
they can legally be placed on the market without the need of either a medicines product licence (PL) or a 107 
traditional herbal medicinal product registration (THR). However, there are several R. rosea products available 108 
that are registered herbal medicinal products for use in the treatment of stress-induced fatigue, exhaustion 109 
and anxiety. 110 
Products registered under the THR scheme must demonstrate that they are safe and of acceptable quality, 111 
including adherence to good agricultural and collection practices (GACP) and good manufacturing practice 112 
(GMP).  113 
Aims and Objectives 114 
To select a sample of Rhodiola products, available from the internet and from retail outlets and assess their 115 
phytochemical composition. 116 
To determine whether there are phytochemical differences between registered products and unregistered 117 
products and to assess how this impacts on the products’ quality (and thus on safety as well as consumer 118 
confidence). 119 
Materials and methods 120 
Test samples 121 
Approximately 40 products were obtained from different suppliers including retail outlets and products that 122 
are readily available over the Internet. The samples claimed to be consisted of crude drug material (2), bulk 123 
powder (3), hard capsule extracts (21), soft gel capsules (1), tablets (9), of Rhodiola rosea and aqueous extracts 124 
of Rhodiola crenulata (3). 37 were mono-preparations claiming to contain only Rhodiola rosea root and 125 
rhizome extracts (and excipients), and two were combined with other constituents such as vitamins, and 126 
herbal extracts. Two of the products held a traditional herbal registration (THR), but the majority were not 127 
registered products and were readily available over the Internet and from retail outlets (as food supplements).  128 
A detailed description of all investigated products is provided in the supplementary data.                              129 
Solvents, reagents and chemicals 130 
Deuterated  dimethyl sulfoxide-D6 lot no. 14F-145 and tetramethylsilane (99.9%) lot no S47541 32108B02 131 
were purchased from Cambridge Isotope Laboratories, Inc., Andover, MA, USA. Ethanol absolute (99.8%), lot 132 
no 950-0090 purchased from Merck, Germany, Methanol, lot no 982801 purchased from CarlRoth GmbH, 133 
Karlsruhe, Germany, Ethylacetate (99.5%), lot no A0343909 purchased from Acros, New Jersey, USA, Formic 134 
acid (98+ %) pure, lot no A0333265 purchased from Acros, New Jersey, USA.  135 
 136 
 137 
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Standards 138 
Reference standard: Salidroside, lot no BCBH4124V and rosavin, lot no 083M4725V were purchased from 139 
Sigma-Aldrich Chemicals, St Luis, MO, USA.  140 
¹H-NMR spectroscopy 141 
Preparations of standard solutions and samples 142 
Approximately 50 mg of solid samples was accurately weighed and transferred to a 1.5 ml Eppendorf reaction 143 
tube, 1 ml of deuterated DMSO containing 0.05% tetramethylsilane were added. The mixture was mixed on a 144 
rotary mixer for 60 s, sonicated for 10 minutes at room temperature and centrifuged for 10 minutes at room 145 
temperature (speed; 14,000 rpm). The reference standard solutions of salidroside, and rosavin were prepared 146 
at a concentration of 1.0 mg/ml in deuterated DMSO. Seven hundred microliters of supernatant was 147 
transferred to a 5 mm diameter NMR tube, and the samples were submitted on the same day for ¹H-NMR 148 
analysis.  Sample 39 was extracted twice (S40) to act as a control for the statistical analysis. 149 
Apparatus and instrumentation 150 
NMR spectra were recorded on Bruker Avance 500MHz spectrometer (
1
H, 500MHz) equipped with a QNP 151 
multi-nuclear probe head with z-gradient . The topspin software version 1.3 was used for spectra acquisition 152 
and processing. The AMIX Bruker Biospin multivariate analysis software version 3.0 was used for converting 153 
spectra to an ASCII file. The numbers of scans chosen was 64 for optimum resolution of peaks, and locked at 154 
zero on the TMS peak. Principal Component Analysis (PCA) carried out using SIMCA software version 13.0. 155 
LC-MS/MS Analysis 156 
Preparations of standard solutions and samples 157 
One mg of substance was suspended in 1 mL of solvent A (2.5 % (v/v) MeCN, 0.5 % (v/v) HCOOH in water), 158 
sonicated for 10 minutes and centrifuged at room temperature for 10 minutes at 5000 g. 159 
Apparatus and instrumentation 160 
The LC-MS/MS data was acquired with an Agilent 1100 HPLC system which was coupled to a Bruker Daltonics 161 
Esquire HCT ion-trap mass detector. 10 µL of the supernatant were used as injection volume for the HPLC. The 162 
chromatographic step was performed with a constant flow rate of 0.2 ml/min and a 45 minutes linear gradient 163 
from solvent A to solvent B (95% MeCN (v/v), 0.5% (v/v) HCOOH in water). For separation, a Waters Atlantis T3 164 
column (2.1 x 150 mm, Silica 3µm) was used which was heated to 50°C. 165 
Data reduction and multivariate statistics methods  166 
The ¹H-NMR spectra were phase-corrected, baseline-corrected, and zeroed to the TMS peak. The spectra were 167 
converted to an ASCII file using AMIX software for multivariate analysis.  AMIX was used to generate a number 168 
of integrated regions (buckets) of the data set. The size of buckets was 0.04 ppm. The signals of deuterated 169 
DMSO, residual water, and TMS internal standard were removed before performing the statistical analysis. The 170 
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data set was imported to Microsoft EXCEL, and the samples were labelled 1 to 40. The Principal Component 171 
Analysis (PCA) was carried out using SIMCA software version 13.0. 172 
High performance thin layer chromatography (HPTLC)  173 
Preparations of standard solutions and samples 174 
The extraction of plant sample was performed based on a method described by the HPTLC association for the 175 
identification of dried Rhodiola root. The reference standard solutions of salidroside and rosarin were 176 
prepared at concentration of 1.0 mg/ml in methanol. Approximately 500 mg of solid samples were weighed 177 
individually into 10 ml reaction tubes and 5 ml of ethanol (99.8 %) was added. The resultant solution was 178 
shaken at 300 rpm for 10 minutes and centrifuged for 5 minutes at 5000 rpm. The supernatant solution was 179 
transferred into individual vials, and then submitted for HPTLC analysis. 180 
Chromatography 181 
HPTLC analysis was performed on 200.0 * 100.0 mm silica gel 60 F 254 HPTLC glass plates (Merck, Germany). 182 
Standard solutions and samples (2 µl) were applied on the plate as bands 8.0 mm wide using CAMAG spray-on 183 
technique with Automatic TLC sampler (ATS 4) or CAMAG Linomat 5.  184 
Bands were applied to a distance of 8.0 mm from the lower edge of plate and 20 mm from the left and right 185 
edges. The space between bands was 11 mm, and the number of tracks per-plate was 15. The development 186 
distance was 70.0 mm from the lower edge of the plate using CAMAG Automatic developing chamber (ADC2). 187 
The temperature and the relative humidity within the developing chamber (ADC2) were 23 ⁰ C and 33 % 188 
respectively.  189 
The derivatisation of plates was performed through dipping (Speed: 3, time:0) with 10 % sulphuric acid in 190 
methanol reagent using CAMAG Chromatogram Immersion Device and heated to 100 ⁰C for 5 minutes on the 191 
TLC plate heater. The plates were documented using CAMAG Visualizer under white light, UV 254 nm, and UV 192 
366 nm with visionCATS software.     193 
Other Apparatus and instrumentation 194 
POS-3000, Grantbio, Serial no b090250014, Cambridgeshire, England. 195 
Centrifuge EBA21, Serial no 0000799-01-00, Hettich (Zentrifugen), Faust Laborbedarf AG, Germany. Balance 196 
AG245, Serial no 1114402254, Mettler-Toledo. 197 
Results and Discussion 198 
The samples were analysed by ¹H-NMR spectroscopy coupled with SIMCA multivariate analysis software, mass 199 
spectrometry and HPTLC.  200 
In the ¹H-NMR spectroscopy analysis, the two main constituents of R. rosea root, salidroside and rosavin were 201 
assigned and compared with a Rhodiola rosea crude dried plant root supplied by a company that manufactures 202 
THR products (S35).  203 
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 204 
Figure 1 ¹H-NMR spectra of Rhodiola rosea crude dried plant (top) together with spectra of reference standards 205 
of salidroside (middle) and rosavin (bottom) respectively. 206 
Because of the high concentration of glycosides, including polysaccharides and the presence of excipients in 207 
many of the Rhodiola products, it was difficult to identify peaks in the carbohydrate range (3 - 5 ppm).   The 208 
resonances observed at lower chemical shifts (0.2-3.0 ppm) are most probably attributable to the methyl 209 
groups of terpenoids (Fig. 1). However, peaks corresponding to salidroside and rosavin could be observed in 210 
the aromatic region of the spectrum (6.2-8.5 ppm) (Fig. 2). Using this method we were able to confirm the 211 
presence of both saldroside and rosavin in our samples. 212 
 213 
Figure 2 ¹H-NMR spectra of  R. rosea extract (top) together with spectra of reference standards of salidroside 214 
(middle) and rosavin (bottom), respectively, focusing on aromatic region. 215 
8 
 
The PCA model for the ¹H-NMR spectroscopy (Fig. 3), utilises data obtained for the entire spectral region (0 – 216 
10 ppm). The Rhodiola products PCA appeared to indicate that although there was much variation between 217 
samples, the variation did not distinguish between the different species. The principal variation between these 218 
two species is rosavin content. 219 
 220 
Figure 3 Scores plot showing the whole spectral regions of investigated Rhodiola samples  221 
The PCA grouping in Fig. 3 may be attributable to the similarities of major metabolites, e.g. glycosidic 222 
constituents within Rhodiola products or to ingredients added (mainly excipients) to the commercial extracts. 223 
This PCA model appeared to poorly discriminate between products containing R. rosea extracts and those 224 
extracts containing Rhodiola crenulata or other Rhodiola species.  Our assumption was that this observation 225 
was possibly due to adulteration of products by incorrect species, i.e. that a proportion of products labelled R. 226 
rosea actually contained an amount of R. crenulata or other species.  In order to investigate this hypothesis, 227 
subsequent analysis was performed utilising HPTLC. 228 
 229 
We developed an HPTLC method in order to simultaneously detect the presence of rosavin and salidroside. 230 
Importantly, R. rosea contains both salidroside (RF 0.35) and rosavin (RF 0.22), whereas although salidroside is 231 
present in many other Rhodiola species, rosavin is absent or in very low concentrations (Panossian 2010). The 232 
characteristic marker compound rosavin was not found in seven of the products claiming to be R. rosea and 233 
the overall fingerprint looked very different to that of R. rosea (Fig 4).  234 
Sample (S) 11 was a registered product and S20 was an expired R. rosea product that we included to see if the 235 
marker compounds were still visible past the expiry date. 236 
 237 
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 238 
Figure 4 Comparing different Rhodiola products, Mobile phase: Ethylacetate, methanol, water, formic acid 239 
(77:13:10:2). D: Sulphuric acid reagent, UV 366 nm.  240 
 241 
The HPTLC analysis revealed that S2, S3, S15, S17, and S21 samples show a fingerprint not consistent with that 242 
of Rhodiola rosea and  were probably adulterated with other Rhodiola species that did not contain rosavin (RF 243 
0.2)  but contained salidroside (RF 0.35) e.g. Rhodiola crenulata, Rhodiola quadrifida. Moreover, two of the 244 
samples exhibited the presence of unspecified components, not related to R. rosea or Rhodiola species (S8 and 245 
S13).  246 
S2 displayed a strong zone at RF 0.92, S13 displayed brightly coloured greenish zones (RF 0.3 and 0.4) S8 247 
appeared not to contain any compounds detectable under this system.  248 
After discovering that these seven samples were adulterated either with other Rhodiola species or unknown 249 
species, it was possible for us to re-label the assigned samples in the NMR - PCA.  250 
Once re-labelled, the PCA displayed an improved differentiation between the R. rosea and Rhodiola crenulata 251 
samples (Fig. 5). Although we have re-labelled five of the products that did not contain rosavins as R. crenulata 252 
it should be recognised that these may be adulterated with other Rhodiola species and we are currently 253 
developing methods that will identify adulterant species within mixtures. 254 
 255 
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 256 
Figure 5 Scores plot showing the whole spectral regions of investigated Rhodiola samples after re-labelling 257 
based on HPTLC identification of the possible source species 258 
Analysis of the raw NMR spectroscopy data for S8 in the aromatic region lead to the identification of signals 259 
which are characteristic for derivatives of the amino acid tryptophan. A downfield shifted signal at 10.6ppm 260 
was characteristic for an indole ring-NH. Closer analysis of the coupling pattern for resonances between 261 
6.5ppm and 7.1ppm identified a lack of a carbon bound proton at position 5 of the indole moiety. This led to 262 
the assumption, that the substance is 5-hydroxytryptophan (5-HTP). This assumption was proved by comparing 263 
NMR (Fig. 6) and LC-MS/MS spectra (Fig. 7) of a commercial sample of 5-HTP with S8. Both, the NMR and the 264 
LC-MS/MS spectra confirmed a presence of 5-HTP in S8 with the same resonances, elution times and 265 
molecular masses, respectively. 266 
 267 
Figure 6 NMR spectrum in 6.5ppm to 7.2 region for sample 8 and 5-HTP commercial sample 268 
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 269 
 270 
Figure 7 LC-MS/MS chromatogram with the mass spectra and fragmentations in positive and negative ion 271 
mode for 5-HTP reference standard and S8. The elution fraction at 7.1 min for 5-HTP with its characteristic 272 
fragmentation is also detectable for S8. 273 
 274 
One of the problematic factors in the metabolomic analysis of commercial products is the presence of 275 
excipients. These tend to occur within the carbohydrate region and, in order to minimise the effect of any 276 
excipient, we performed a PCA exclusively on the aromatic region (7 – 10ppm).  277 
In order to compare only the aqueous and hydro-ethanolic extract products, the crude raw drugs (samples 1, 278 
34 and 35) were removed from the data set, together with the unknown products (samples 8 and 13) and a 279 
soft-gel extract (sample 28). The resulting PCA showed a better differentiation between R. rosea and the non-280 
rosea species. Further investigations will determine whether these are R. crenulata  or other adulterant 281 
Rhodiola species (Fig. 8).  282 
It is observed that the products that are highest in rosavin are in the bottom right quadrant. There is a group of 283 
seven products that are higher in rosavin content than other products, including the 2 THR products (11 and 284 
33). However, there are some R. rosea products that appear to have a very low rosavin content; in fact the PCA 285 
places these more closely to the group we have labelled R. crenulata products (samples 5 and 6). The likely 286 
reason for this is that these products contain a mixture of R. rosea and R. crenulata or other adulterant 287 
species. Through closer examination of this PCA we can infer that over 80% of products contain less rosavin 288 
than the THR products.  289 
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 290 
Figure 8 Scores plot showing PCA of Rhodiola products (7 – 10 ppm chemical shift).The lower ellipse indicates 291 
products that are higher in rosavin content. 292 
Table 1 Label claims versus actual findings for Rhodiola products 293 
Sample no.  Findings 
2 Rhodiola rosea sourced in China Not R. rosea, probably other rhodiola 
species e.g. R. crenulata 
3 Whole dried root of Rhodiola rosea Not R. rosea, probably other rhodiola 
species e.g. R. crenulata 
8 Rhodiola rosea extract 2000 mg, 
wild-sourced from Siberia 
Not R. rosea or any other R. species. 
Determined as 5-HTP and excipients 
13 Rhodiola rosea root 1000 mg Probably not rhodiola species, appears 
adulterated   
15 Rhodiola rosea plus multivitamins 
standardised to contain 3% rosavins 
and 1% salidroside 
Not R. rosea, probably other rhodiola 
species e.g. R. crenulata 
17 Rhodiola rosea standardised to 
contain 1% salidroside 
Not R. rosea, probably other rhodiola 
species e.g. R. crenulata 
21 Rhodiola rosea standardised to 
contain 1% salidroside 
Not R. rosea, probably other rhodiopla 
species e.g. R. crenulata.  Probable high 
sugar content 
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General Discussion 294 
The safety and quality of herbal medicines available to European consumers has been a key issue for 295 
medicines regulators. The introduction of the Traditional Herbal Medicinal Products Directive (THMPD) and 296 
herbal registration has provided a means whereby consumers can access a wide variety of popular herbal 297 
medicines of assured quality and with a well-researched safety profile. 298 
However, there are still a large number of medicines left un-regulated and widely available, particularly from 299 
internet sources. Economically lucrative products, including R. rosea products, are likely candidates for 300 
adulteration, especially when the raw plant material is in short supply. Moreover, because R. rosea products 301 
are popular with sports persons, there is an added danger that they may be adulterated with performance 302 
enhancing stimulants. 303 
Using a methodology previously developed by our group (Booker et al., 2014), we investigated the utilisation 304 
of ¹H-NMR spectroscopy coupled with multivariate analysis software and HPTLC to ascertain the identity and 305 
composition of  R. rosea value chain products. Both techniques provide different and complementary data, 306 
which we used to discriminate between the wide-variety of sampled finished products. Further investigations 307 
will focus on the crude drug material and aim to establish a robust method for identifying mixtures of different 308 
species within products.   309 
¹H-NMR spectroscopy coupled with multivariate analysis software enabled us to group the Rhodiola products 310 
based on similarities between the products. Although chemometric data analysis can be undertaken 311 
automatically with the requisite software packages, it requires an in-depth understanding as to what each set 312 
of signals in the given spectra represents phytochemically, so that the identification of key constituents within 313 
a product can be assigned logically.  In this set of samples (mainly extracts) there were a lot of overlapping 314 
peaks present, particularly in the carbohydrate region, probably produced by a combination of intrinsic 315 
glycosidic material and excipients. This made interpretation of the data difficult for individual compounds and 316 
suggested that a more separation technique, e.g. HPTLC should be used. 317 
The HPTLC analysis provided detailed qualitative data for the determination of the marker compounds, and 318 
allowed to make visual comparisons between different products relatively easily. Because HPTLC allows us to 319 
be selective regarding the groups of compounds we want to analyse, we can make comparisons between 320 
samples based on the composition of the main marker compounds (salidroside and rosavin). 321 
Rhodiola crenulata is the main species found in Chinese medicine and it is the only species listed in the Chinese 322 
Pharmacopoeia. However, R. rosea is the species of main economic interest. The difference in price between 323 
the two species, with R. crenulata being cheaper for the foreign buyer, and the relative ease of availability in 324 
China of R. crenulata, may be a reason behind the adulteration of R. rosea products with R. crenulata and 325 
possibly other Rhodiola species. While there is – at this stage – no evidence for potential risks in using Rhodiola 326 
crenulata, apart from a possible lack of effectiveness, other examples of phytomedicines highlight the risk of 327 
adulteration with a species of the same genus (Li and Yu, 2006).  328 
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In this study, the characteristic marker compound (rosavin) was not detected in twenty three percent of 329 
unregistered products that claimed to contain R. rose . Two of these products were adulterated with material 330 
not from the genus Rhodiola i.e. that did not contain either rosavin or salidroside and one of these was 331 
positively identified as 5-hydroxytryptophan, an amino acid commonly used as an anti-depressant or   an aid 332 
for weight loss. It is unclear whether this is a deliberate or accidental adulteration since attempts to clarify this 333 
with the companies involved have been unsuccessful. However, whether deliberate or not, these findings 334 
show that there is a monumental failing in the quality systems of the companies involved. 335 
Moreover, there were variations in the amount of marker compounds contained in Rhodiola products. This 336 
was supported by the PCA data which indicated that approximately 80% of products contained lower amounts 337 
of rosavin than the THR products. Thus, this may indicate that there are common but qualitative different 338 
species of Rhodiola substituted or used as admixtures in R. rosea labelled products.   339 
While adulteration by other Rhodiola species, including Rhodiola crenulata presents one particular problem, 340 
adulteration with unknown material is potentially even more worrying. Future investigations will focus on the 341 
isolation and identification of these compounds to determine whether there are other plant species or 342 
synthetic compounds (including stimulants) and how different value chains are affected. 343 
Conclusions 344 
Approximately one quarter of unregistered Rhodiola products were adulterated and did not conform to their 345 
label specification.  Approximately 80% of products were of poorer quality than the THR products as regards 346 
the rosavin content. This indicates that there are major breakdowns in the quality systems employed along the 347 
various stages of Rhodiola value chains. 348 
Buying unregistered products, particularly from the internet, presents a clear risk. There is no practical way for 349 
the general public to differentiate un-registered genuine products from adulterated products. Products 350 
registered under the THMPD were confirmed to contain authentic RR.   351 
Based on this analysis we plan to investigate the value chains of R. rosea and other Rhodiola species and to 352 
investigate how and why such adulterations can happen. This research also calls for more training and for 353 
raising awareness of the relevant stakeholders.  354 
 355 
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